Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.Blue DNA illustrationPhoto of a series of test tubes.Scientific microscope with visual representation of DNA helix

Trethera Receives $2 Million National Cancer Institute Grant for Advancement of Clinically Relevant Biomarkers in Phase 1 Trial

May 30, 2023

Trethera was awarded a $2M NCI SBIR grant to advance biomarker development in its Phase 1 dose escalation trial of TRE‑515 in solid tumors. The funding supports patient dosing studies to identify predictive biomarkers of activity and target engagement.

Read More

Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid Tumor Patients

March 15, 2023

Trethera completed Phase 1a dose escalation of TRE‑515 in heavily pretreated solid tumor patients. Results showed no dose-limiting toxicities up to 320 mg, favorable pharmacokinetics, dose-proportional exposure, biomarker engagement, and an SRC recommendation to continue the trial.

Read More

Trethera Announces Appointment of Laurent Dubois to Board of Directors

February 15, 2023

Trethera has appointed Laurent Dubois, a healthcare executive with experience at McKinsey & Company and GE Healthcare, to its Board of Directors. He will also chair the Board’s Compensation Committee, strengthening governance as TRE‑515 moves toward clinical milestones.

Read More

Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

January 24, 2023

Trethera will showcase a poster by UCLA’s Dr. Peter Clark at the ACTRIMS MS Annual Meeting, demonstrating that TRE‑515, a dCK inhibitor, blocks lymphocyte proliferation and MS symptoms in mouse models, with relevance to optic neuritis and other demyelinating diseases.

Read More

Trethera Announces Appointment of R. Boyd Quinnell to Board of Directors

January 18, 2023

Trethera has appointed R. Boyd Quinnell, CPA MBA and seasoned healthcare executive, to its Board of Directors as an independent director. He will also chair the Board’s Audit Committee, bringing deep financial leadership experience in medical technology.

Read More